

Wan-Fai Ng

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5047701/wan-fai-ng-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

122 papers	4,947 citations	36 h-index	68 g-index
139 ext. papers	6,072 ext. citations	5.4 avg, IF	4.99 L-index

#	Paper	IF	Citations
122	Addressing the clinical unmet needs in primary Sjögren's Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts.. <i>Computational and Structural Biotechnology Journal</i> , 2022 , 20, 471-484	6.8	0
121	Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial. <i>Lancet Rheumatology, The</i> , 2021 , 3, e337-e346	14.2	7
120	Revisiting the JOQUER trial: stratification of primary Sjögren's syndrome and the clinical and interferon response to hydroxychloroquine. <i>Rheumatology International</i> , 2021 , 41, 1593-1600	3.6	2
119	Autonomic Nervous System Dysfunction in Primary Sjögren's Syndrome. <i>Frontiers in Immunology</i> , 2021 , 12, 702505	8.4	2
118	Improvement of Severe Fatigue Following Nuclease Therapy in Patients With Primary Sjögren's Syndrome: A Randomized Clinical Trial. <i>Arthritis and Rheumatology</i> , 2021 , 73, 143-150	9.5	14
117	Reply. <i>Arthritis and Rheumatology</i> , 2021 , 73, 718-719	9.5	
116	The management of Sjögren's syndrome: British Society for Rheumatology guideline scope. <i>Rheumatology</i> , 2021 , 60, 2122-2127	3.9	0
115	A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome. <i>Rheumatology</i> , 2021 , 60, 1364-1375	3.9	10
114	New developments in Sjogren's syndrome.. <i>Rheumatology</i> , 2021 , 60, vi53-vi61	3.9	1
113	Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome. <i>Drugs and Aging</i> , 2021 , 38, 265-284	4.7	0
112	Fatigue in inflammatory rheumatic diseases: current knowledge and areas for future research. <i>Nature Reviews Rheumatology</i> , 2021 , 17, 651-664	8.1	7
111	Genetic variants at the locus are associated with fatigue in Scandinavian patients with primary Sjögren's syndrome.. <i>RMD Open</i> , 2021 , 7,	5.9	1
110	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 166-174	2.2	0
109	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium.. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 133, 166-174	2.2	
108	Targeting the rheumatoid arthritis synovial fibroblast via cyclin dependent kinase inhibition: An early phase trial. <i>Medicine (United States)</i> , 2020 , 99, e20458	1.8	10
107	Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren's syndrome. <i>Rheumatology International</i> , 2020 , 40, 541-548	3.6	13
106	Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study. <i>Lancet Rheumatology, The</i> , 2020 , 2, e142-e152	14.2	34

105	Vagus nerve stimulation for autoimmune rheumatic diseases. <i>Lancet Rheumatology, The</i> , 2020 , 2, e512-e513	5.1	3
104	EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 3-18	2.4	139
103	Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren's syndrome. <i>Rheumatology</i> , 2020 , 59, 2350-2359	3.9	24
102	Nodular localized primary cutaneous amyloidosis and primary Sjögren's syndrome. <i>Scandinavian Journal of Rheumatology</i> , 2020 , 49, 159-160	1.9	3
101	Weight of salivary gland ultrasonography compared to other items of the 2016 ACR/EULAR classification criteria for Primary Sjögren's syndrome. <i>Journal of Internal Medicine</i> , 2020 , 287, 180-188	10.8	26
100	Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 126, 85-94	2.2	1
99	Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. <i>Lancet Rheumatology, The</i> , 2019 , 1, e85-e94	14.2	38
98	Managing fatigue in patients with primary Sjögren's syndrome: challenges and solutions. <i>Open Access Rheumatology: Research and Reviews</i> , 2019 , 11, 77-88	2.4	12
97	Between a ROC and a hard place: Teaching prevalence plots to understand real world biomarker performance in the clinic. <i>Pharmaceutical Statistics</i> , 2019 , 18, 632-635	1	2
96	Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren's syndrome. <i>RMD Open</i> , 2019 , 5, e000885	5.9	9
95	Positive anti-MOG antibodies in a patient with Sjögren's syndrome and transverse myelitis. <i>European Journal of Rheumatology</i> , 2019 , 6, 102-104	1.7	4
94	Network structure underpinning (dys)homeostasis in chronic fatigue syndrome; Preliminary findings. <i>PLoS ONE</i> , 2019 , 14, e0213724	3.7	5
93	Fatigue in primary Sjögren's syndrome (pSS) is associated with lower levels of proinflammatory cytokines: a validation study. <i>Rheumatology International</i> , 2019 , 39, 1867-1873	3.6	14
92	Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome. <i>RMD Open</i> , 2019 , 5, e001064	5.9	24
91	MtDNA population variation in Myalgic encephalomyelitis/Chronic fatigue syndrome in two populations: a study of mildly deleterious variants. <i>Scientific Reports</i> , 2019 , 9, 2914	4.9	14
90	AB0184 FLOW CYTOMETRIC IMMUNOPHENOTYPING OF SALIVARY GLANDS IN PRIMARY SJÖGREN'S SYNDROME 2019 ,		13
89	Supervised walking improves cardiorespiratory fitness, exercise tolerance, and fatigue in women with primary Sjögren's syndrome: a randomized-controlled trial. <i>Rheumatology International</i> , 2019 , 39, 227-238	3.6	12
88	The Effects of Noninvasive Vagus Nerve Stimulation on Fatigue and Immune Responses in Patients With Primary Sjögren's Syndrome. <i>Neuromodulation</i> , 2019 , 22, 580-585	3.1	33

87	A two-phase cohort study of the sleep phenotype within primary Sjögren's syndrome and its clinical correlates. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 118, 78-82	2.2	4
86	Systemic interferon type I and type II signatures in primary Sjögren's syndrome reveal differences in biological disease activity. <i>Rheumatology</i> , 2018 , 57, 921-930	3.9	48
85	Experience of sleep disruption in primary Sjögren's syndrome: A focus group study. <i>British Journal of Occupational Therapy</i> , 2018 , 81, 218-226	1	7
84	Mixed-Methods Study Identifying Key Intervention Targets to Improve Participation in Daily Living Activities in Primary Sjögren's Syndrome Patients. <i>Arthritis Care and Research</i> , 2018 , 70, 1064-1073	4.7	8
83	Effect of rituximab on a salivary gland ultrasound score in primary Sjögren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 412-416	2.4	53
82	B-cell activity markers are associated with different disease activity domains in primary Sjögren's syndrome. <i>Rheumatology</i> , 2018 , 57, 1222-1227	3.9	18
81	Reduction of Glucocorticoid Receptor Function in Chronic Fatigue Syndrome. <i>Mediators of Inflammation</i> , 2018 , 2018, 3972104	4.3	7
80	Anti-Ro antibodies and complete heart block in adults with Sjögren's syndrome. <i>European Journal of Rheumatology</i> , 2018 , 5, 194-196	1.7	4
79	Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry. <i>Swiss Medical Weekly</i> , 2018 , 148, w14588	3.1	6
78	Mitochondrial DNA copy number is not associated with fatigue status in Primary Sjögren's Syndrome** Denote corporate authorship (see appendix for list of members)View all notes. <i>Fatigue: Biomedicine, Health and Behavior</i> , 2018 , 6, 123-131	2.3	2
77	How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 112, 102-112	2.2	34
76	Physical activity but not sedentary activity is reduced in primary Sjögren's syndrome. <i>Rheumatology International</i> , 2017 , 37, 623-631	3.6	10
75	Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1161-1168	2.4	133
74	Randomized Controlled Trial of Rituximab and Cost-Effectiveness Analysis in Treating Fatigue and Oral Dryness in Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1440-1450	9.5	122
73	A new MHC-linked susceptibility locus for primary Sjögren's syndrome: MICA. <i>Human Molecular Genetics</i> , 2017 , 26, 2565-2576	5.6	14
72	Clinically proven mtDNA mutations are not common in those with chronic fatigue syndrome. <i>BMC Medical Genetics</i> , 2017 , 18, 29	2.1	14
71	Subjective and Objective Measures of Dryness Symptoms in Primary Sjögren's Syndrome: Capturing the Discrepancy. <i>Arthritis Care and Research</i> , 2017 , 69, 1714-1723	4.7	12
70	Identification of a Sjögren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons. <i>PLoS Genetics</i> , 2017 , 13, e1006820	6	41

69	309. IT ISN'T PAIN PURE AND SIMPLE: EXPERIENCES OF PAIN AND DISCOMFORT IN PRIMARY SJÖGREN'S SYNDROME: A QUALITATIVE FOCUS GROUP STUDY. <i>Rheumatology</i> , 2017 , 56,	3.9	4
68	Salivary gland ultrasound abnormalities in primary Sjögren's syndrome: consensual US-SG core items definition and reliability. <i>RMD Open</i> , 2017 , 3, e000364	5.9	64
67	Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2017 , 69, 2187-2192	9.5	29
66	What impact does written information about fatigue have on patients with autoimmune rheumatic diseases? Findings from a qualitative study. <i>Musculoskeletal Care</i> , 2017 , 15, 230-237	1.6	5
65	The British Society for Rheumatology guideline for the management of adults with primary Sjögren's Syndrome. <i>Rheumatology</i> , 2017 , 56, e24-e48	3.9	9
64	The British Society for Rheumatology guideline for the management of adults with primary Sjögren's Syndrome. <i>Rheumatology</i> , 2017 , 56, 1643-1647	3.9	4
63	An investigation into the prevalence of sleep disturbances in primary Sjögren's syndrome: a systematic review of the literature. <i>Rheumatology</i> , 2017 , 56, 570-580	3.9	13
62	Eligibility for clinical trials in primary Sjögren's syndrome: lessons from the UK Primary Sjögren's Syndrome Registry. <i>Rheumatology</i> , 2016 , 55, 544-52	3.9	7
61	Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 382-9	2.4	144
60	Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations. <i>Expert Review of Clinical Immunology</i> , 2016 , 12, 137-56	5.1	83
59	Germline variation of TNFAIP3 in primary Sjögren's syndrome-associated lymphoma. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 780-3	2.4	29
58	X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1290-1300	9.5	65
57	289 A Cytokine-Mediated Biological Basis for Fatigue in Primary Sjögren's Syndrome. <i>Rheumatology</i> , 2016 , 55, i179-i179	3.9	1
56	Rheumatoid Factor and Disease Activity Are Independent Predictors of Lymphoma in Primary Sjögren's Syndrome. <i>Arthritis and Rheumatology</i> , 2016 , 68, 977-85	9.5	106
55	Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokines. <i>RMD Open</i> , 2016 , 2, e000282	5.9	46
54	Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome. <i>Clinical Immunology</i> , 2016 , 168, 25-29	9	41
53	Do the EULAR Sjögren's syndrome outcome measures correlate with health status in primary Sjögren's syndrome?. <i>Rheumatology</i> , 2015 , 54, 655-9	3.9	19
52	Retrospective analysis of the role of serum vitamin D in early rheumatic disease. <i>Rheumatology</i> , 2015 , 54, 374-5	3.9	3

51	Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. <i>Rheumatology</i> , 2015 , 54, 2230-8	3.9	150
50	Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 859-66	2.4	138
49	The IRF5-TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. <i>Human Molecular Genetics</i> , 2015 , 24, 582-96	5.6	57
48	EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide. <i>RMD Open</i> , 2015 , 1, e000022	5.9	150
47	A systematic review of non-pharmacological interventions for primary Sjögren's syndrome. <i>Rheumatology</i> , 2015 , 54, 2025-32	3.9	14
46	A Transcriptional Signature of Fatigue Derived from Patients with Primary Sjögren's Syndrome. <i>PLoS ONE</i> , 2015 , 10, e0143970	3.7	24
45	Intramolecular polyspecificity in CD4 T-cell recognition of Ad-restricted epitopes of proteoglycan aggrecan. <i>Immunology</i> , 2014 , 142, 101-110	7.8	
44	Health-related utility values of patients with primary Sjögren's syndrome and its predictors. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1362-8	2.4	63
43	Testing the role of vitamin D in response to antitumour necrosis factor α therapy in a UK cohort: a Mendelian randomisation approach. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 938-40	2.4	6
42	Developing a service user informed intervention to improve participation and ability to perform daily activities in primary Sjögren's syndrome: a mixed-methods study protocol. <i>BMJ Open</i> , 2014 , 4, e006264	2.4	5
41	Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. <i>Pharmacogenomics Journal</i> , 2014 , 14, 171-5	3.5	3
40	Facial nerve compression by the posterior inferior cerebellar artery causing facial pain and swelling: a case report. <i>Journal of Medical Case Reports</i> , 2014 , 8, 105	1.2	
39	Cardiovascular risk factors in women with primary Sjögren's syndrome: United Kingdom primary Sjögren's syndrome registry results. <i>Arthritis Care and Research</i> , 2014 , 66, 757-64	4.7	40
38	Systematic Reviews of Occupational Therapy Interventions: Summarizing Research Evidence and Highlighting the Gaps. <i>British Journal of Occupational Therapy</i> , 2014 , 77, 479-482	1	5
37	IDIOPATHIC AXONAL NEUROPATHY AND PRIMARY SJOĞREN'S SYNDROME. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, e4.87-e4	5.5	
36	Orthostatic intolerance is common in chronic disease--a clinical cohort study. <i>International Journal of Cardiology</i> , 2014 , 174, 861-3	3.2	8
35	Association of genes in the NF- κ B pathway with antibody-positive primary Sjögren's syndrome. <i>Scandinavian Journal of Immunology</i> , 2013 , 78, 447-54	3.4	37
34	Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. <i>Nature Genetics</i> , 2013 , 45, 1284-92	36.3	322

33	Cardiovascular risk in juvenile idiopathic arthritis. <i>Rheumatology</i> , 2013 , 52, 1163-71	3.9	39
32	High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. <i>Nature Genetics</i> , 2012 , 44, 1336-40	36.3	436
31	Impaired functional status in primary Sjögren's syndrome. <i>Arthritis Care and Research</i> , 2012 , 64, 1760-4	4.7	48
30	Potential diagnostic utility of anti-centromere antibody in primary Sjögren's syndrome in the UK. <i>Clinical Rheumatology</i> , 2012 , 31, 1147-8	3.9	5
29	Heterogeneity of anticitrullinated peptide antibodies and response to anti-tumor necrosis factor agents in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2012 , 39, 929-32	4.1	16
28	Sjögren's syndrome - an update for dental practitioners. <i>British Dental Journal</i> , 2012 , 213, 353-7	1.2	29
27	Occupational Therapy: A Potentially Valuable Intervention for People with Primary Sjögren's Syndrome. <i>British Journal of Occupational Therapy</i> , 2012 , 75, 247-249	1	4
26	Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sjogren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1973-9	2.4	46
25	Primary Sjogrens syndrome is associated with impaired autonomic response to orthostasis and sympathetic failure. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2012 , 105, 1191-9	2.7	17
24	Prevalence and diagnostic outcome relating to vitamin D deficiency in new patients presenting to an early arthritis clinic over 12 months. <i>Clinical Rheumatology</i> , 2011 , 30, 1137-8	3.9	3
23	Invariant natural killer T (iNKT) cell deficiency in chronic mucocutaneous candidiasis--a consequence or a cause?. <i>Immunology Letters</i> , 2011 , 135, 180-3	4.1	2
22	United Kingdom Primary Sjogren's Syndrome Registry--a united effort to tackle an orphan rheumatic disease. <i>Rheumatology</i> , 2011 , 50, 32-9	3.9	52
21	Biological therapies in primary Sjögren's syndrome. <i>Expert Opinion on Biological Therapy</i> , 2011 , 11, 921-36	5.4	7
20	Measurement of Quality of Life in Primary Sjögren's Syndrome		1
19	Primary Sjogren's syndrome: too dry and too tired. <i>Rheumatology</i> , 2010 , 49, 844-53	3.9	88
18	Profound invariant natural killer T-cell deficiency in inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010 , 69, 1873-9	2.4	24
17	Impaired T(H)17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. <i>Journal of Allergy and Clinical Immunology</i> , 2010 , 126, 1006-15, 1015.e1-4	11.5	50
16	Response of Th17 cells to a citrullinated arthritogenic aggrecan peptide in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2010 , 62, 143-9		77

15	Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2009 , 9, 909-19	5.4	34
14	Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. <i>Nature Genetics</i> , 2009 , 41, 1313-8	36.3	272
13	Expansion of hepatitis C-specific CD4+CD25+ regulatory T cells after viral clearance: a mechanism to limit collateral damage?. <i>Journal of Allergy and Clinical Immunology</i> , 2008 , 121, 1277-1284.e3	11.5	15
12	From mice to men: the challenges of developing tolerance-inducing biological drugs for the clinic 2008 , 169-185		1
11	In vivo evidence for apoptosis in the bone marrow in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66, 1106-9	2.4	37
10	Fluoroquinolone-associated tendinopathy: a case report. <i>Journal of Medical Case Reports</i> , 2007 , 1, 55	1.2	10
9	Quantitating effector and regulatory T lymphocytes in immune responses by limiting dilution analysis modeling. <i>Journal of Immunology</i> , 2005 , 174, 3421-31	5.3	4
8	Cutting edge: CTLA-4 (CD152) differentially regulates mitogen-activated protein kinases (extracellular signal-regulated kinase and c-Jun N-terminal kinase) in CD4+ T cells from receptor/ligand-deficient mice. <i>Journal of Immunology</i> , 2002 , 169, 3475-9	5.3	58
7	Reversibility with interleukin-2 suggests that T cell anergy contributes to donor-specific hyporesponsiveness in renal transplant patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2002 , 13, 2983-9	12.7	26
6	Human CD4+ CD25+ T cells regulate CD8+ T-cell activation. <i>Transplantation Proceedings</i> , 2002 , 34, 2858-60		2
5	Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. <i>Blood</i> , 2001 , 98, 2736-44		508
4	Dendritic cells in transplantation--friend or foe?. <i>Immunity</i> , 2001 , 14, 357-68	32.3	251
3	The role of T-cell anergy in the maintenance of donor-specific hyporesponsiveness in renal transplant recipients. <i>Transplantation Proceedings</i> , 2001 , 33, 154-5	1.1	7
2	Predictive value of in vitro assessment of direct alloresponses in transplant recipients?. <i>Transplantation</i> , 2001 , 72, 772-3	1.8	
1	Invariant Natural Killer T Cells in Rheumatoid Arthritis and Other Inflammatory Arthritides		2